Cyclooxygenase 2 Inhibitors
"Cyclooxygenase 2 Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A subclass of cyclooxygenase inhibitors with specificity for CYCLOOXYGENASE-2.
| Descriptor ID |
D052246
|
| MeSH Number(s) |
D27.505.519.389.310.500 D27.505.696.663.850.014.040.500.500.500 D27.505.954.158.030.500.500 D27.505.954.329.030.500.500
|
| Concept/Terms |
Cyclooxygenase 2 Inhibitors- Cyclooxygenase 2 Inhibitors
- Inhibitors, Cyclooxygenase 2
- Cyclooxygenase-2 Inhibitors
- Inhibitors, Cyclooxygenase-2
- Coxibs
- COX-2 Inhibitors
- COX 2 Inhibitors
- Inhibitors, COX-2
- COX2 Inhibitors
- Inhibitors, COX2
|
Below are MeSH descriptors whose meaning is more general than "Cyclooxygenase 2 Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Cyclooxygenase 2 Inhibitors".
This graph shows the total number of publications written about "Cyclooxygenase 2 Inhibitors" by people in this website by year, and whether "Cyclooxygenase 2 Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 2 | 2 |
| 2002 | 0 | 6 | 6 |
| 2003 | 1 | 4 | 5 |
| 2004 | 0 | 7 | 7 |
| 2005 | 0 | 3 | 3 |
| 2006 | 4 | 1 | 5 |
| 2007 | 1 | 0 | 1 |
| 2008 | 1 | 2 | 3 |
| 2011 | 1 | 0 | 1 |
| 2012 | 0 | 1 | 1 |
| 2013 | 1 | 0 | 1 |
| 2014 | 1 | 1 | 2 |
| 2015 | 1 | 1 | 2 |
| 2017 | 2 | 0 | 2 |
| 2021 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cyclooxygenase 2 Inhibitors" by people in Profiles.
-
Wang D, Cabalag CS, Clemons NJ, DuBois RN. Cyclooxygenases and Prostaglandins in Tumor Immunology and Microenvironment of Gastrointestinal Cancer. Gastroenterology. 2021 12; 161(6):1813-1829.
-
Thomas D, Zachariah S, Sundararaj KGS, Van Cuyk M, Cooper JC. Authors' Reply to Urtasun et al.: "Coxibs Refocus Attention on the Cardiovascular Risks of Non-Aspirin NSAIDs". Am J Cardiovasc Drugs. 2017 12; 17(6):497-498.
-
Thomas D, Ali Z, Zachariah S, Sundararaj KGS, Van Cuyk M, Cooper JC. Coxibs Refocus Attention on the Cardiovascular Risks of Non-Aspirin NSAIDs. Am J Cardiovasc Drugs. 2017 Oct; 17(5):343-346.
-
Wang D, Fu L, Sun H, Guo L, DuBois RN. Prostaglandin E2 Promotes Colorectal Cancer Stem Cell Expansion and Metastasis in Mice. Gastroenterology. 2015 Dec; 149(7):1884-1895.e4.
-
Zeng C, Wei J, Li H, Yang T, Gao SG, Li YS, Xiong YL, Xiao WF, Luo W, Yang TB, Lei GH. Comparison between 200 mg QD and 100 mg BID oral celecoxib in the treatment of knee or hip osteoarthritis. Sci Rep. 2015 May 27; 5:10593.
-
Kim SH, Margalit O, Katoh H, Wang D, Wu H, Xia D, Holla VR, Yang P, DuBois RN. CG100649, a novel COX-2 inhibitor, inhibits colorectal adenoma and carcinoma growth in mouse models. Invest New Drugs. 2014 Dec; 32(6):1105-1112.
-
Zhang Y, Hoda MN, Zheng X, Li W, Luo P, Maddipati KR, Seki T, Ergul A, Wang MH. Combined therapy with COX-2 inhibitor and 20-HETE inhibitor reduces colon tumor growth and the adverse effects of ischemic stroke associated with COX-2 inhibition. Am J Physiol Regul Integr Comp Physiol. 2014 Sep 15; 307(6):R693-703.
-
Misra S, Ghatak S, Patil N, Dandawate P, Ambike V, Adsule S, Unni D, Venkateswara Swamy K, Padhye S. Novel dual cyclooxygenase and lipoxygenase inhibitors targeting hyaluronan-CD44v6 pathway and inducing cytotoxicity in colon cancer cells. Bioorg Med Chem. 2013 May 01; 21(9):2551-9.
-
Furuya H, Wada M, Shimizu Y, Yamada PM, Hannun YA, Obeid LM, Kawamori T. Effect of sphingosine kinase 1 inhibition on blood pressure. FASEB J. 2013 Feb; 27(2):656-64.
-
Oates JC, Halushka PV, Hutchison FN, Ruiz P, Gilkeson GS. Selective cyclooxygenase-2 inhibitor suppresses renal thromboxane production but not proliferative lesions in the MRL/lpr murine model of lupus nephritis. Am J Med Sci. 2011 Feb; 341(2):101-5.